ClinicalTrials.gg
Not yet recruitingNCT06461676Updated Mar 10, 2025

Study of Intramyocardial Injection of Ventrix Bio Extracellular Matrix (VentriGel) to Assess the Safety and Feasibility in Pediatric Patients with Hypoplastic Left Heart Syndrome (HLHS)

A Phase 1 interventional study of Ventrix Bio Extracellular Matrix in Hypoplastic Left Heart Syndrome, sponsored by Emory University. Not yet recruiting at 1 site in United States. Open to participants aged Up to 1 Year. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by Emory University · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
Up to 1 Year
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Hypoplastic Left Heart Syndrome with a site in United States — 6 open to participants now, 10 under way, 1 of them phase 3. Hypoplastic Left Heart Syndrome · United States.

Planned enrollment
22nd of 26
12 · median 30
Started
2025
with 1 other
Phase 1
9 of 44
1 open now
Registered
42nd of 44
by date
Lead sponsor
5 of 44
Emory University

Among the 44 studies in Hypoplastic Left Heart Syndrome with a site in United States, this one is the 22nd largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 in phase 1, and was the 42nd registered.

Hypoplastic Left Heart Syndrome

67 studies on the registry are indexed under Hypoplastic Left Heart Syndrome; 12 are open to participants now.

Browse Hypoplastic Left Heart Syndrome studies →

Open to participants now

6 of the 44 studies in Hypoplastic Left Heart Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Hypoplastic Left Heart Syndrome studies recruiting now, 3 set no upper age limit and 6 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: Up to 1 Year · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Hypoplastic Left Heart Syndrome with a site in United States, or all of them as a file.
02

Study summary

The goal of this Phase I Open-Label study is to demonstrate the safety and feasibility of VentriGel injection in children with Hypoplastic Left Heart Syndrome (HLHS).

The main questions it aims to answer are:

  • Whether VentriGel is safe in treating patients with HLHS
  • Whether there are any preliminary improvements in measures of cardiac function following Ventrigel injection
Read the detailed description

HLHS, a type of congenital heart disease, presents a unique challenge where the left ventricle fails to develop, necessitating the right ventricle to manage both systemic and pulmonary blood flow. This condition, once fatal, has become manageable due to advancements in surgical techniques, with reported 5-year survival rates of 70-90%. However, these staged procedures, while lifesaving, can strain the right ventricle, leading to long-term issues such as weakened muscle and reduced cardiac function. Additionally, even with surgical intervention, patients often face a diminished quality of life.

Addressing these challenges, ongoing clinical trials explore regenerative therapies, particularly stem cell injections, aiming to improve heart function. Yet, concerns persist regarding the practicality and efficacy of these treatments, including issues with cell survival and coordination of injections within narrow timeframes.

Innovatively, the investigator and the team propose an alternative approach using VentriGel, an injectable hydrogel derived from decellularized porcine myocardium. Originally designed for treating heart failure post-myocardial infarction in adults, VentriGel has shown promising results in animal models, demonstrating significant improvements in cardiac function. Notably, its shelf-stable nature and flexible timing for administration offer advantages over traditional stem cell therapies.

Moreover, VentriGel's effectiveness in addressing right-ventricular failure, as demonstrated in recent studies, highlights its potential as a solution for HLHS patients. Leveraging approved extracellular matrix devices, such as Alloderm and SurgiSIS, further underscores the feasibility and safety of this approach, paving the way for potentially transformative treatments in congenital heart diseases.

03

Conditions studied

  • Hypoplastic Left Heart Syndrome

Keywords

  • Stage II Glenn operation
  • HLHS
04

Who can participate

Ages eligible
Up to 1 Year
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with Hypoplastic Left Heart Syndrome (HLHS) requiring Stage II Glenn operation under one year of age

Exclusion criteria

Exclusion Criteria:

  • Subjects undergoing the Stage II Glenn operations who do not have HLHS
  • Subjects requiring mechanical circulatory support within 5 days pre pre-surgical intervention
  • Parent or guardian unwilling or unable to comply with necessary follow-up(s)
  • diseases or subjects who require treatment with interventions that cause immunosuppression
  • A history of tumor or
  • Coagulation disorders
  • Chromosomal abnormalities that limit expected survival to \< 1 year
  • Abnormal lab values that may increase the risk of the study procedure (WBC >20,000 cells/ul or \< 1,000 cells/ul; count \< 50,000 cells/ul; \< 8.0 gm/dl; LFTs > 2x reference lab ) at the time of screening
  • Subjects with conduction abnormalities, including atrioventricular block and bundle branch blocks
  • Ventricular arrhythmias due to antiarrhythmic pharmacological therapy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Ventrix Bio Extracellular Matrix

    Treatment intervention of a total of 8 injections into the right ventricle of the heart will occur before the patient comes off of the heart-lung bypass machine used during the Stage II Glenn Operation. The treatment will be conducted according to clinical guidelines set in place while the patient is undergoing a surgical intervention before the patient comes off the heart/lung bypass machine required for the stage II Glenn Procedure.

    Drug: Ventrix Bio Extracellular Matrix

Interventions

  • DrugVentrix Bio Extracellular Matrix

    VentriGel will be administered by injection into the right ventricle of the heart in the following defined doses per injection. There will be a total of 8 injections. The proposed dose of up to 0.6 mL is administered as up to 8 sequential injections of 4 injections of 0.1 mL each and 4 injections of 0.05 mL each.

    Also known as: VentriGel

06

What researchers measure

Primary outcomes

  1. Number of ventricular tachycardia events

    Number of sustained/symptomatic ventricular tachycardia incidences requiring intervention with inotropic support or anti-arrhythmics

    Time frame: upto 30 days post operation

  2. Number of Cardiogenic shock events

    Cardiogenic shock (i.e. tissue hypoperfusion presented by hypotension due to decreased cardiac output, determined by rising lactate levels (5x normal levels in first 24 hours, 2.5x normal levels in first 30 days)

    Time frame: Day 1, 30 days post operation

  3. Number of unplanned cardiovascular operation events

    Unplanned cardiovascular operation due to right ventricular intramyocardial injection site bleeding in the first 5 days after Stage II operation decreased cardiac output, determined by rising lactate levels (5x normal levels in first 24 hours, 2.5x normal levels in first 30 days)

    Time frame: 30 days post operation

  4. Number of patients requiring new permanent pacemaker

    Number of patients requiring new permanent pacemaker

    Time frame: upto 30 days post operation

  5. Stroke or embolic event

    Stroke or embolic event to the brain determined by CT scan

    Time frame: upto 30 days post operation

  6. Number of Adverse Events

    Number of adverse events occurring post op

    Time frame: upto 30 days post operation

  7. Number of deaths

    Number of deaths occurring post op

    Time frame: upto 30 days post operation

  8. Number of VentriGel products manufactured and delivered to subjects

    Time frame: 12 months

  9. Number of patients receiving Cardiac MRIs

    Time frame: Baseline, 6 months, 12 months

Secondary outcomes

  1. Change in right ventricular ejection fraction

    This will be measured by serial echocardiograms and MRI scans

    Time frame: Baseline, 6 months, 12 months post operation

  2. Change in right ventricular end diastolic volume

    This will be measured by serial echocardiograms and MRI scans

    Time frame: Baseline, 6 months, 12 months post operation

  3. Change in right ventricular end systolic volume

    This will be measured by serial echocardiograms and MRI scans

    Time frame: Baseline, 6 months, 12 months post operation

  4. Change in tricuspid regurgitation

    This will be measured by serial echocardiograms and MRI scans. tricuspid regurgitation measured by tricuspid valve vena contracta width

    Time frame: Baseline, 6 months,12 months post operation

  5. Change in right ventricular function Fractional Area Change

    This will be measured by serial transthoracic echocardiogram (TTE)

    Time frame: Baseline, 6 months,12 months post operation

  6. Change in right ventricular global longitudinal strain

    This will be measured by serial transthoracic echocardiogram (TTE)

    Time frame: Baseline, 6 months,12 months post operation

  7. Change in right ventricular global circumferential strain

    This will be measured by serial transthoracic echocardiogram (TTE)

    Time frame: Baseline, 6 months,12 months post operation

  8. Change in right ventricular Tricuspid Annular Plane Systolic Excursion (TAPSE)

    This will be measured by serial transthoracic echocardiogram (TTE)

    Time frame: Baseline, 6 months,12 months post operation

  9. Change in right atrial volume indexed

    This will be measured by serial transthoracic echocardiogram (TTE)

    Time frame: Baseline, 6 months,12 months post operation

07

Study locations

1 site
  • Children's Healthcare of Altanta
    Atlanta, Georgia 30322, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Sep 2028, 37 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2024
First posted
Jun 17, 2024
StartEst.
Aug 2025
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06461676
Lead sponsor
Emory University
Collaborators
Ventrix, Inc., University of California, San Diego
Responsible party
William T. Mahle (Professor, Emory University) — Principal investigator
First posted
Jun 17, 2024
Start date
Aug 2025 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Mar 10, 2025

Study contacts

William Mahle, MD
Contact
MahleW@kidsheart.com
404-256-2593
William Mahle, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion